![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol
Departments of Medicine (N.G., Y.D., M.R., S.G.), Biochemistry (S.G.), Pharmacology (S.G.), and Radiation Oncology (P.D.), Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia
Interactions between the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitors (HDACIs) sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) have been examined in human leukemia cells in relation to effects on nuclear factor 
B (NF-B) activation. Exposure (24 h) of U937 human leukemia cells to NaB (1 mM) or SAHA (1.5 µM) resulted in a marked increase in NF-B DNA binding, effects that were essentially abrogated by coadministration of flavopiridol (100 nM). These events were accompanied by a marked increase in mitochondrial injury, caspase activation, and apoptosis. Mutant cells expressing an IB
super-repressor exhibited impairment of NF-B DNA binding in response to HDACIs and a significant although modest increase in apoptosis. However, disruption of the NF-B pathway also increased mitochondrial injury and caspase activation in response to flavopiridol and to an even greater extent to the combination of flavopiridol and HDACIs. Coadministration of flavopiridol with HDACIs down-regulated the X-linked inhibitor of apoptosis (XIAP), Mcl-1, and p21CIP1/WAF1 and activated c-Jun NH2-terminal kinase; moreover, these effects were considerably more pronounced in IB mutants. Similar responses were observed in U937 mutant cells stably expressing RelA/p65 small interfering RNA. In all cases, flavopiridol was significantly more potent than genetic interruption of the NF-B cascade in promoting HDACI-mediated lethality. Together, these findings are consistent with the notion that although inhibition of NF-B activation by flavopiridol contributes to antileukemic interactions with HDACIs, other NF-B–independent flavopiridol actions (e.g., down-regulation of Mcl-1, XIAP, and p21CIP1/WAF1) play particularly critical roles in this phenomenon.
Received for publication April 29, 2004.
Accepted for publication July 2, 2004.
Address correspondence to: Dr. Steven Grant, Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond, VA 23298. E-mail: stgrant{at}hsc.vcu.edu
This article has been cited by other articles:
|
|
 |
|
  K. Shiozawa, T. Nakanishi, M. Tan, H.-B. Fang, W.-c. Wang, M. J. Edelman, D. Carlton, I. Gojo, E. A. Sausville, and D. D. Ross Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias Clin. Cancer Res., March 1, 2009; 15(5): 1698 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zhang, M. A. Park, C. Mitchell, H. Hamed, M. Rahmani, A. P. Martin, D. T. Curiel, A. Yacoub, M. Graf, R. Lee, et al. Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation Clin. Cancer Res., September 1, 2008; 14(17): 5385 - 5399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Smith, V. Cimica, S. Chinni, K. Challagulla, S. Mani, and G. V. Kalpana Rhabdoid Tumor Growth is Inhibited by Flavopiridol Clin. Cancer Res., January 15, 2008; 14(2): 523 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Andresen, H. Jensen, M. T. Pedersen, K. A. Hansen, and S. Skov Molecular Regulation of MHC Class I Chain-Related Protein A Expression after HDAC-Inhibitor Treatment of Jurkat T Cells J. Immunol., December 15, 2007; 179(12): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, and P. Dent Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3101 - 3112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, S. Coe, M. S. Gimenez, P. Dent, and S. Grant Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Mol. Cancer Ther., February 1, 2007; 6(2): 692 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Palacios, R. Yerbes, and A. Lopez-Rivas Flavopiridol Induces Cellular FLICE-Inhibitory Protein Degradation by the Proteasome and Promotes TRAIL-Induced Early Signaling and Apoptosis in Breast Tumor Cells. Cancer Res., September 1, 2006; 66(17): 8858 - 8869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gao, L. Kramer, M. Rahmani, P. Dent, and S. Grant The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism Mol. Pharmacol., August 1, 2006; 70(2): 645 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, Y. Liu, H. Liu, P. L. Hermonat, and J. L. Mehta Molecular Dissection of Angiotensin II-Activated Human LOX-1 Promoter Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1163 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takada, A. Gillenwater, H. Ichikawa, and B. B. Aggarwal Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation J. Biol. Chem., March 3, 2006; 281(9): 5612 - 5622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Schwartz Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. El-Deiry Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance Cancer Res., June 1, 2005; 65(11): 4475 - 4484. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
